---
---
4:15-4:30 p.m. | Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade*
Kristen Pauken, The University of Texas MD Anderson Cancer Center, Houston, Texas

---

# Doctrine: The Logistics of War - Engineering T-Cell Recruitment

This doctrine is built upon the foundational discovery that T-cell therapies are not just a battle of soldiers, but a war of **logistics**. The speaker has brilliantly proven that the highways between the lymph node "barracks" and the tumor "battlefield" are the most critical, controllable axis in the entire conflict. She has invented a brilliant camera to watch the traffic. We will now provide the fucking air traffic control tower and the combat engineering corps.

---

## **Part I: The Discovery - The Battlefield Is a Supply Chain Problem**

Her work has definitively shifted the paradigm from the tumor microenvironment to the entire macro-environment.

### **Her Breakthrough: The "Timestamp" Weapon**
*   **The Problem:** It was impossible to distinguish fresh-faced recruits from exhausted, battle-worn veterans within a tumor, making it impossible to study the logistics of the T-cell response.
*   **Her Solution:** A simple, powerful IV antibody injection that acts as a **timestamp**. It cleanly separates newly arrived T-cells (<72 hours) from the resident population.
*   **The Power:** For the first time, she can accurately measure the flow of reinforcements to the front lines.

### **Her Core Intel:**
1.  **The Supply Lines Collapse:** As tumors grow, T-cell recruitment plummets. The highways shut down.
2.  **Reinforcements Win the War:** Newly recruited T-cells are fitter and less exhausted.
3.  **Checkpoint Inhibitors are a Logistics Drug:** Anti-PD-1's primary mechanism of action is to **double the number of fresh recruits** arriving at the tumor. It's not just waking up tired soldiers; it's calling in the cavalry.
4.  **Autoimmunity is the Same War:** The same highways are used by autoimmune T-cells to invade and destroy healthy tissue.

**Her Grand Unified Theory:** The war against cancer and autoimmunity will be won or lost on the battlefield of **T-cell migration.**

---

## **Part II: Our Solution - From Measurement to Engineering**

### **The Positioning: Intelligence First, Weapons Second**

**What We're NOT Claiming:**
- ❌ We don't have the answer (we don't know WHY recruitment collapses yet)
- ❌ We can't predict bottlenecks from RNA-seq alone (untested, literature r = 0.3-0.5)
- ❌ One intervention won't work for all tumors (different bottlenecks need different solutions)

**What We CAN Do:**
- ✅ Diagnose WHY recruitment fails (RNA-seq → bottleneck classification)
- ✅ Design precision interventions (4 different solutions, one per bottleneck type)
- ✅ Test our hypotheses with YOUR data (8-week pilot, $0 cost)

---

### **The Opportunity: Answer Her Unanswered Questions**

**Question 1: WHY Does Recruitment Collapse?**
- **Our Tool:** Bottleneck Diagnostic (RNA-seq → Type A/B/C/D classification)
  - Type A: Chemokine Desert (low CXCL9/CXCL10/CCL5)
  - Type B: Physical Barrier (high fibrosis/COL1A1/FAP)
  - Type C: Suppressor Dominant (high TGFB/IDO/VEGF)
  - Type D: Vascular Collapse (low vessel markers)
- **Value:** She knows WHICH tumors need WHICH intervention (not guessing)

**Question 2: WHICH Chemokines Actually Matter?**
- **Our Tool:** Correlation Analysis (genes vs her timestamp-measured recruitment)
- **Value:** Discover which chemokines ACTUALLY drive recruitment (not assumed)

**Question 3: CAN We Rescue Collapsed Recruitment?**
- **Our Tool:** Precision Intervention Designs (4 different approaches)
  - Type A → Chemokine overexpression cassette
  - Type B → Stromal remodeling (CRISPRi + MMP)
  - Type C → Suppressor neutralization (anti-TGFβ/VEGF)
  - Type D → Vascular normalization (VEGF + ANGPT1)
- **Value:** Test RIGHT intervention on RIGHT tumor (de-risk experiments)

**Question 4: Block Autoimmunity WITHOUT Blocking Tumor Immunity?**
- **Our Tool:** Comparative Analysis (pancreas vs tumor RNA-seq)
- **Value:** Identify tissue-specific or timing-based selectivity

---

### **The 8-Week Pilot: Test Our Hypotheses**

**Input:** 20-30 tumors with RNA-seq + timestamp flow data (HIGH vs LOW recruitment)

**Deliverables:**
1. Bottleneck heatmap (which tumors have which problem)
2. Gene signature (top 20 genes predicting recruitment collapse)
3. Anti-PD-1 response predictor (baseline biomarker)
4. 5 intervention designs (one per bottleneck + combination)
5. Validation protocols (how to test each design)

**Cost:** $0. Co-author if it works. You keep everything if it fails.

**Success Criteria:** r > 0.60 for RNA-seq → bottleneck prediction  
**Pivot Plan:** If r < 0.50, recommend spatial RNA-seq and re-train

---

### **The Pitch (30 Seconds):**

> **Dr. Pauken,**
>
> Your timestamp tool proves recruitment collapses. But you don't know WHY.
>
> Give us your timestamp data + RNA-seq (30 samples). In 8 weeks, we'll tell you:
> - Which tumors have which bottleneck (chemokines? barriers? suppressors?)
> - Which chemokines actually predict recruitment (not assumed)
> - 5 intervention designs (one per bottleneck type)
>
> **Cost: $0**. Co-author + co-own IP if it works. You keep everything if it fails.
>
> This de-risks your next 3 years of experiments.
